Isotretinoin in Treatment of COVID-19 (Randomized)
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Isotretinoin, COVID-19
Eligibility Criteria
Inclusion Criteria:
- Clinical and laboratory diagnosis of COVID-19.
- Age range 18-40
Exclusion Criteria:
- Hypercholesterolemia
- Hypertriglyceridemia
- Liver disease
- Renal disease
- Sjögren syndrome
- Pregnancy
- Lactation
- Depressive disorder
- Contraindications for hormonal contraception or intrauterine device.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Sham Comparator
Active Comparator
Isotretinoin
Standard COVID-19 therapy
Standard COVID-19 therapy+ isotretinoin
13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally for one month
Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases
Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) plus 13 cis retinoic acid 0.5 mg/kg/day in 2 divided doses orally forone month.